1-3 of 3
Adrianne Kelly
Close
Sort by
Journal Articles

Estimating Mortality in Patients with Hematological Malignancy and COVID-19: A Pooled Analysis of 10 Studies

Kamal S. Saini, MD, Marco Tagliamento, Matteo Lambertini, Richard McNally, Adrianne Kelly, Marco Romano, Isagani Chico, Taylor Jenson, Steven M Anderson, PhD, Giuseppe Curigliano, Evandro de Azambuja
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-141749
Published: 2020
Journal Articles

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Jennifer R Brown, MD, PhD, Matthew S. Davids, MD, Jordi Rodon, MD, Pau Abrisqueta, MD, Arthur P. DeCillis, MD, MS, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Farrukh T Awan, MD, MS
Journal: Blood
Blood (2011) 118 (21): 2683.
https://doi.org/10.1182/blood.V118.21.2683.2683
Published: 2011
Journal Articles

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Kyriakos P Papadopoulos, MD, Pau Abrisqueta, MD, Glenda Chambers, BSN, RN, OCN, CCRC, Drew Rasco, MD, Amita Patnaik, Josep Tabernero, MD, Kanya Rajangam, MD, PhD, Kevin Rockich, Coumaran Egile, Adrianne Kelly, MD, Yi Xu, Joanne Lager, MD, Julie M Vose, MD
Journal: Blood
Blood (2011) 118 (21): 1608.
https://doi.org/10.1182/blood.V118.21.1608.1608
Published: 2011